Henoch-Schonlein Purpura in a Patient with Ankylosing Spondylitis after Infliximab Therapy / 대한내과학회지
Korean Journal of Medicine
;
: 764-768, 2013.
Artigo
em Coreano
| WPRIM
| ID: wpr-35120
ABSTRACT
Tumor necrosis factor alpha (TNF-alpha) inhibitors are used widely to treat patients with active rheumatoid arthritis and ankylosing spondylitis (AS). Although various cutaneous reactions can occur as side effects of TNF-alpha inhibitors, systemic vasculitis requiring withdrawal of the agent and immunosuppressive drugs is rare. A 59-year-old male with AS who had been treated with infliximab for 60 months visited us with complaints of palpable purpura on both legs and severe abdominal pain. Abdominal computed tomography showed diffuse wall thickening of the proximal jejunum and ileum and a skin biopsy revealed leukocytoclastic vasculitis. The patient was diagnosed with Henoch-Schonlein purpura (HSP). Infliximab was discontinued and systemic steroid therapy at 0.5 mg/kg resulted in prompt resolution of the HSP. Here, we report the first case of HSP in a patient with AS after infliximab treatment.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Artrite Reumatoide
/
Púrpura
/
Vasculite por IgA
/
Pele
/
Espondilite Anquilosante
/
Vasculite
/
Biópsia
/
Dor Abdominal
/
Fator de Necrose Tumoral alfa
/
Vasculite Leucocitoclástica Cutânea
Limite:
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS